Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo(1,2-b)pyrazol-3-yl)quinoline-6-carboxylic Acid Amide
2. Ly 2157299
3. Ly-2157299
4. Ly2157299
1. 700874-72-2
2. Ly2157299
3. Ly 2157299
4. Ly-2157299
5. 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide
6. Unii-3okh1w5lze
7. Ly2157299(galunisertib)
8. Galunisertib (ly2157299)
9. Galunisertib [usan]
10. 3okh1w5lze
11. 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide
12. 4-[2-(6-methylpyridin-2-yl)-4h,5h,6h-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
13. 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
14. Galunisertib (usan)
15. 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4h-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide
16. 6-quinolinecarboxamide, 4-(5,6-dihydro-2-(6-methyl-2-pyridinyl)-4h-pyrrolo(1,2-b)pyrazol-3-yl)-
17. Galunisertib [usan:inn]
18. Galunisertibum
19. 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo(1,2-b)pyrazol-3-yl)quinoline-6-carboxamide
20. Galunisertib [inn]
21. 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo(1,2-b)pyrazol-3-yl)quinoline-6-carboxylic Acid Amide
22. Galunisertib [who-dd]
23. Gtpl7797
24. Chembl2364611
25. Schembl12922153
26. Amy9045
27. Dtxsid00220362
28. Ex-a009
29. Chebi:137064
30. Hms3655d14
31. Bcp02173
32. Zinc3959536
33. Bdbm50015640
34. Mfcd12923319
35. Nsc761216
36. Nsc800103
37. S2230
38. Akos022175280
39. Ccg-264950
40. Cs-0474
41. Db11911
42. Ex-8675
43. Nsc-761216
44. Nsc-800103
45. Sb16483
46. Lyl-2157299
47. Ncgc00384167-07
48. Ac-31327
49. As-42940
50. Hy-13226
51. Inhibitor 15d [pmid: 18314943]
52. Ft-0741808
53. Sw219460-1
54. D10437
55. A836766
56. J-514250
57. Q27077768
58. 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide, Aldrichcpr
59. 4-[2-(6-methyl-2-pyridinyl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide
60. 4-[2-(6-methyl-2-pyridinyl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamideorly215
61. 4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxylic Acid Amide
62. 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[2,1-e]pyrazol-3-yl]quinoline-6-carboxamide
63. 6-quinolinecarboxamide, 4-(5,6-dihydro-2-(6-methyl-2-pyridinyl)-4h-pyrrolo(1,2-b)pyrazol-3-yl)-)
| Molecular Weight | 369.4 g/mol |
|---|---|
| Molecular Formula | C22H19N5O |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 369.15896025 g/mol |
| Monoisotopic Mass | 369.15896025 g/mol |
| Topological Polar Surface Area | 86.7 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 585 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
53
PharmaCompass offers a list of Galunisertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Galunisertib manufacturer or Galunisertib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galunisertib manufacturer or Galunisertib supplier.
PharmaCompass also assists you with knowing the Galunisertib API Price utilized in the formulation of products. Galunisertib API Price is not always fixed or binding as the Galunisertib Price is obtained through a variety of data sources. The Galunisertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Galunisertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galunisertib, including repackagers and relabelers. The FDA regulates Galunisertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galunisertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Galunisertib supplier is an individual or a company that provides Galunisertib active pharmaceutical ingredient (API) or Galunisertib finished formulations upon request. The Galunisertib suppliers may include Galunisertib API manufacturers, exporters, distributors and traders.
Galunisertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Galunisertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Galunisertib GMP manufacturer or Galunisertib GMP API supplier for your needs.
A Galunisertib CoA (Certificate of Analysis) is a formal document that attests to Galunisertib's compliance with Galunisertib specifications and serves as a tool for batch-level quality control.
Galunisertib CoA mostly includes findings from lab analyses of a specific batch. For each Galunisertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Galunisertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Galunisertib EP), Galunisertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galunisertib USP).
